Top 3 Picks
2026 Outlook
Looking ahead to 2026, the biotech sector is poised for growth fueled by increasing R&D investments, projected to reach $300 billion globally, and a surge in personalized therapies that could capture a 20% market share in oncology. Trends such as AI integration in drug development and expanded gene editing applications are expected to drive efficiency and reduce costs, potentially leading to a 15-20% annual revenue growth for leading firms. Despite potential headwinds like regulatory hurdles and economic uncertainty, the sector's outlook remains optimistic, with opportunities in emerging areas like cell-based treatments and rare disease therapies.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Passage Bio, Inc. Common Stock
|
68.8 | $11.69 | $26M |
|
2
|
Novavax Inc
|
67.9 | $7.13 | $1.5B |
|
3
|
Alector, Inc. Common Stock
|
63.9 | $1.53 | $304M |
|
4
|
Kyverna Therapeutics, Inc. Common Stock
|
63.0 | $8.77 | $258M |
|
5
|
Gilead Sciences Inc
|
62.6 | $121.60 | $137.9B |
|
6
|
enGene Holdings Inc. Warrants
|
62.5 | $2.96 | -- |
|
7
|
Adverum Biotechnologies, Inc. Common Stock
|
62.4 | $4.36 | $105M |
|
8
|
ImageneBio, Inc. Common Stock
|
62.4 | $6.76 | $95M |
|
9
|
Atara Biotherapeutics, Inc
|
62.2 | $17.77 | $101M |
|
10
|
Halozyme Therapeutics, Inc.
|
62.1 | $70.31 | $8.8B |
|
11
|
Cardiff Oncology, Inc. Common Stock
|
61.8 | $2.66 | $138M |
|
12
|
Exelixis Inc
|
61.6 | $43.58 | $11.1B |
|
13
|
Bio-Techne Corp.
|
61.6 | $59.65 | $9.3B |
|
14
|
Ocugen, Inc. Common Stock
|
61.5 | $1.38 | $525M |
|
15
|
Vaxcyte, Inc. Common Stock
|
61.3 | $46.46 | $4.9B |
In-Depth Analysis: Top Biotech Stocks
PASG
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Passage Bio matters in the Biotech sector as it specializes in developing gene therapies for rare monogenic CNS disorders, such as GM1 Gangliosidosis and Krabbe Disease, addressing critical unmet needs in genetic medicine. Its focused pipeline positions the company as a key innovator in advancing treatments for these underserved conditions, potentially driving broader industry progress in rare disease therapies.
Passage Bio's ROE of -87.2% indicates significant financial challenges, reflecting losses and inefficient use of equity in its early-stage development efforts. However, a Tradestie Score of 68.8 suggests moderate underlying potential, possibly due to its promising pipeline, though this does not offset current unprofitability concerns.
By 2026, Passage Bio's pipeline advancements in therapies for GM1 Gangliosidosis and Krabbe Disease could lead to successful clinical trials and FDA approvals, potentially unlocking substantial revenue growth in the expanding gene therapy market. The company's Tradestie Score of 68.8 signals reasonable investment fundamentals, supporting optimism for partnerships or acquisitions that could enhance stock value. Additionally, as a pure-play in rare CNS disorders, Passage Bio is well-positioned to capitalize on increasing demand for personalized medicines, making it an attractive buy for long-term investors seeking biotech upside.
NVAX
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology …
Novavax Inc matters in the Biotech sector as a leader in clinical-stage vaccine development, focusing on novel candidates to prevent a wide range of diseases through its collaboration with its Swedish subsidiary, which enhances its capacity for rapid innovation and global health impact.
Novavax demonstrates strong operational efficiency with a 32.1% profit margin, indicating effective cost management in vaccine development. However, its -898.2% ROE and -16.6% revenue growth reveal severe financial strain, pointing to challenges in equity utilization and declining sales that could undermine long-term stability.
By 2026, NVAX's low P/E ratio of 3.3 suggests the stock is undervalued, offering significant upside potential as the company advances its vaccine pipeline and captures growing demand for innovative preventive solutions. The Tradestie Score of 67.9 indicates moderate investment viability, supported by potential revenue recovery from new product launches amid expanding global vaccine markets. Additionally, Novavax's focus on broad-spectrum vaccines positions it to benefit from post-pandemic health priorities and partnerships, driving future growth.
ALEC
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Alector Inc. matters in the Biotech sector due to its innovative focus on developing therapies that restore healthy immune function to combat neurodegeneration, addressing a critical unmet need in an aging global population where neurodegenerative diseases affect over 50 million people worldwide. Its clinical-stage pipeline positions the company as a potential leader in immune-mediated treatments, differentiating it in a competitive market projected to reach $50 billion by 2030.
Alector's profitability is deeply negative, with a profit margin of -156.0% and ROE of -122.0%, indicating substantial operational losses and poor returns on shareholder equity, which are typical for clinical-stage biopharma firms investing heavily in R&D. The -78.8% revenue growth further underscores financial strain, suggesting a need for capital raises or pipeline advancements to improve long-term financial health.
By 2026, Alector's advancing therapies for neurodegeneration could achieve key clinical milestones, such as Phase III trial successes, potentially driving stock value upward given the Tradestie Score of 63.9, which signals moderate investment potential. The growing demand for neurodegeneration treatments, with the market expected to expand at a 7% CAGR through 2030, positions Alector for significant upside if its immune-restoring approach proves effective. Investors should consider buying due to the high-reward nature of biotech, where successful FDA approvals could transform Alector's negative metrics into profitable growth.
KYTX
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in …
Kyverna Therapeutics matters in the Biotech sector due to its innovative focus on cell therapies for autoimmune diseases, a high-unmet-need area affecting millions globally. Its lead product, KYV-101, an autologous CD19 CAR T-cell therapy, represents a potential breakthrough in personalized medicine, positioning the company as a key player in advancing treatments for conditions like multiple sclerosis and lupus.
Kyverna's Return on Equity (ROE) of -70.8% indicates significant financial challenges, typical for clinical-stage biopharmaceutical companies that are investing heavily in research and development without current revenue streams. However, the Tradestie Score of 63.0/100 suggests moderate financial health and investment viability, reflecting potential in their pipeline despite ongoing losses.
By 2026, Kyverna's KYV-101 could advance through clinical trials and gain regulatory approvals, potentially capturing a multi-billion-dollar market in autoimmune therapies as demand grows with an aging population. The company's specialized focus on CAR T-cell treatments aligns with biotech trends toward personalized medicine, supported by a Tradestie Score of 63.0 indicating reasonable upside potential. Successful commercialization could drive substantial stock gains, transforming Kyverna into a profitable leader in the sector as clinical data strengthens investor confidence.
GILD
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology …
Gilead Sciences matters in the Biotech sector as a leading innovator in treatments for HIV and hepatitis, addressing critical global health needs that affect millions worldwide. Its acquisition of Pharmasset and the success of drugs like Sovaldi have established it as a key driver in advancing infectious disease therapies, influencing market standards and competition.
Gilead's 27.9% profit margin and 40.7% ROE indicate strong profitability and efficient use of equity, reflecting solid financial health in the competitive Biotech sector. However, with only 3.0% revenue growth, the company maintains stability rather than aggressive expansion, supported by a P/E ratio of 19.1 that suggests reasonable valuation relative to earnings.
Gilead's established dominance in HIV and hepatitis treatments, combined with its 40.7% ROE and 27.9% profit margin, positions it for sustained demand in 2026 as global infectious disease markets expand. The company's pipeline, including advancements from acquisitions like Pharmasset, could drive new revenue streams amid evolving healthcare needs. At a P/E of 19.1, the stock offers an attractive entry point for investors seeking stability and growth in the Biotech sector by 2026.
ENGNW
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
enGene Holdings Inc. matters in the Biotech sector due to its innovative DDX platform, a proprietary non-viral gene delivery system that enables localized treatments for genetic disorders, potentially addressing unmet needs in areas like oncology and rare diseases with improved safety profiles compared to viral vectors.
With limited financial data available, enGene's Tradestie Score of 62.5/100 indicates moderate financial health for a clinical-stage biotech firm, suggesting potential for growth through milestone achievements but highlighting risks associated with high R&D expenditures and lack of revenue from approved products.
By 2026, enGene's DDX platform could yield positive clinical trial outcomes, potentially leading to strategic partnerships or FDA approvals that drive stock value upward in the expanding gene therapy market. The non-viral approach offers a competitive advantage by reducing safety concerns, positioning enGene for significant upside if it advances its pipeline successfully. Investors may benefit from the sector's projected growth, with gene therapies expected to reach a market size of over $10 billion annually by mid-decade, making ENGNW warrants an attractive speculative opportunity.
ADVM
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to …
Adverum Biotechnologies matters in the Biotech sector due to its focus on gene therapy for prevalent ocular diseases, potentially transforming treatment standards by offering sustained therapeutic protein expression. This approach addresses unmet needs in ophthalmology, positioning the company as a key player in advancing durable, one-time treatments amid growing demand for gene-based solutions.
Adverum's ROE of -417.8% indicates severe unprofitability, highlighting significant losses relative to shareholder equity, which is typical for clinical-stage biotechs but signals financial strain. The -70.0% revenue growth further underscores declining financial health, emphasizing the urgency for positive clinical outcomes to stabilize operations and attract funding.
By 2026, Adverum's gene therapy pipeline for ocular diseases could yield successful clinical trial results, potentially leading to FDA approvals and substantial revenue from partnerships, given the Tradestie Score of 62.4 indicating moderate investment potential. The company's focus on sustained therapeutic expression addresses high unmet needs in prevalent eye disorders, which could drive stock appreciation as the biotech sector expands gene therapy adoption. Additionally, advancements in ocular gene therapy may position ADVM for market leadership, offering investors high upside if regulatory milestones are achieved.
IMA
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
ImageneBio Inc. matters in the Biotech sector due to its focus on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody for atopic dermatitis, addressing a high unmet need in immunological and inflammatory diseases with a potential market exceeding $10 billion annually. This innovation positions the company as a key contributor to advancing targeted therapies in a sector projected to grow at 15% CAGR through 2030.
As a clinical-stage biopharmaceutical company, ImageneBio likely faces negative profitability from substantial R&D investments, with limited financial data indicating ongoing cash burn typical for pre-revenue biotech firms. The Tradestie Score of 62.4/100 reflects moderate financial health, suggesting adequate liquidity for near-term operations but highlighting risks in achieving profitability without successful trials or partnerships.
By 2026, ImageneBio could see significant upside from positive clinical trial results for IMG-007, potentially leading to FDA approval and entry into the atopic dermatitis market, which is expected to expand driven by increasing prevalence and demand for biologics. The company's differentiated therapy approach may attract strategic partnerships or acquisitions, enhancing valuation amid sector growth. Additionally, the Tradestie Score of 62.4 indicates potential for stock appreciation if milestones are met, making it an appealing option for investors focused on biotech innovation.
ATRA
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Atara Biotherapeutics matters in the Biotech sector for its focus on developing innovative therapies for solid tumors, hematologic cancers, and autoimmune diseases, addressing critical unmet needs in oncology and immunology. Its streamlined operation as a single segment enhances efficiency in advancing treatments that could transform patient care and drive sector innovation.
Atara's 15.4% profit margin reflects some operational efficiency in its biotech endeavors, but its financial health is severely compromised by a -2014.9% ROE and -91.4% revenue growth, indicating significant losses and declining business scale. The 6.3 P/E ratio suggests potential undervaluation, yet overall metrics highlight high financial risk.
By 2026, investors should consider buying ATRA due to its promising pipeline of therapies for serious diseases, which could lead to FDA approvals and revenue recovery from the current -91.4% growth slump. The stock's 6.3 P/E ratio indicates it is undervalued compared to peers, presenting a data-driven opportunity for appreciation if clinical successes materialize. Additionally, the 62.2/100 Tradestie Score reflects moderate upside potential, positioning ATRA for growth amid biotech sector advancements.
HALO
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in …
Halozyme Therapeutics matters in the Biotech sector due to its specialized focus on developing innovative oncology therapies that leverage human enzymes to alter tumors, addressing critical unmet needs in cancer treatment. This approach positions the company as a key player in advancing proprietary enzyme-based solutions for therapeutic areas like oncology, as evidenced by its 22.1% revenue growth.
Halozyme exhibits robust profitability with a 47.9% profit margin and an exceptional 124.5% ROE, demonstrating efficient equity utilization and strong financial health. The company's 22.1% revenue growth and a P/E ratio of 14.3 further indicate sustainable earnings potential and a relatively undervalued stock compared to peers.
Investors should consider buying HALO stock in 2026 given its strong revenue growth of 22.1% and high profitability metrics, including a 47.9% profit margin, which signal continued expansion in the oncology market. The company's focus on novel enzyme-based therapies could drive future breakthroughs and market share gains, potentially enhancing shareholder value. Additionally, with a Tradestie Score of 62.1 and a low P/E of 14.3, HALO offers an attractive entry point for growth-oriented investors seeking biotech opportunities.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.